Klin Farmakol Farm. 2018;32(2):3-7 | DOI: 10.36290/far.2018.008

Epidemiological study of new oral anticoagulants

Anna Zatloukalová^1,2, Jana Janoutová³, Miroslav Homza⁴, Vladimír Janout³

¹ Ústav epidemiologie a ochrany veřejného zdraví, Lékařská fakulta, Ostravská univerzita v Ostravě

² Centrum epidemiologického výzkumu, Lékařská fakulta, Ostravská univerzita v Ostravě

³ Centrum vědy a výzkumu, Fakulta zdravotnických věd, Univerzita Palackého, Olomouc

⁴ Kardiovaskulární oddělení, Fakultní nemocnice Ostrava

Purpose: New oral anticoagulants are a big step forward in the area of anticoagulation therapy. They have a large number ofbenefits, whether it is their security profile or the need for monitoring. However, in order to optimize treatment, epidemiologicalresearch should be carried out in this area.

Methods: New data from patients from a network of cardiac outpatients were used in the study of new oral anticoagulants. Theselection criteria were dabigatran, rivaroxaban and apixaban.

Results: Data from 334 patients were analyzed in the study. The male population predominated slightly (55.4%). The most commoninitial diagnosis for prescribing new oral anticoagulants was 68% of atrial fibrillation. 94% of patients have taken these medicinesfor a long time. The least adverse effect was apixaban (8 patients), followed by rivaroxaban with 16 patients and most adverseevents with dabigatran in 18 patients.

Conclusion: Based on epidemiological studies, it is possible to characterize a group of patients using new oral anticoagulantsand to optimize the treatment of each patient effectively.

Keywords: dabigatran, rivaroxaban, apixaban, new oral anticoagulants, epidemiological research

Published: August 13, 2018  Show citation